Source comparison
Best Sermorelin Dosage Growth Hormone Release 2026: Comparison
100–150 mcg 2–4 ng/mL Minimal (5–10% increase) Rare. Occasional mild flushing Subtherapeutic for most adults; not recommended unless hypersensitivity suspected Insufficient to drive meaningful anabolic response. Use only as diagnostic dose 200–300 mcg 8–12 ng/
This comparison does not assign a generated winner or score.
- 100–150 mcg
- 2–4 ng/mL
- Minimal (5–10% increase)
- Rare. Occasional mild flushing
- Subtherapeutic for most adults; not recommended unless hypersensitivity suspected
- Insufficient to drive meaningful anabolic response. Use only as diagnostic dose
- 200–300 mcg
- 8–12 ng/mL
- Moderate (20–35% increase over 8–12 weeks)
- Mild flushing in 10–15% of users; transient tachycardia <5%
- Standard research dosing for GH optimisation in adults 35+
- Optimal dose range. Saturates GHRH receptors without exceeding physiological tolerance
- 400–500 mcg
- 9–13 ng/mL
- Comparable to 200–300 mcg range
- Increased flushing frequency (25–30%); cortisol rebound more common
- No additional GH benefit vs lower doses; receptor saturation already achieved
- Clinically unjustified. Excess dose provides no incremental GH elevation
- >500 mcg
- 10–14 ng/mL
- No incremental benefit
- Frequent flushing, palpitations, cortisol-mediated sleep disruption
- Not recommended. Adverse event risk outweighs marginal GH response
- Hard ceiling. Doses above this range degrade the risk-benefit ratio significantly
- The comparison above underscores a critical point: Sermorelin's dose-response curve plateaus sharply at 300 mcg. The additional 2 ng/mL GH elevation seen at 500+ mcg does not translate to greater IGF-1 synthesis or improved body composition outcomes, but it does trigger cortisol reactivity that can impair sleep architecture. The very window Sermorelin is designed to optimise.